Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Comment by lscfaon Jun 12, 2019 2:54pm
152 Views
Post# 29819458

RE:RE:RE:RE:Oh how the mighty have fallen...

RE:RE:RE:RE:Oh how the mighty have fallen...Get frigging real. PLI was not generating positive cash flow, NRI is.......


Cubalibra wrote: Correct. Going close to zero when loans are called. Just look at PLI. $3.60 to $0.02 and shares from 750 million to 30 billion on loan restructure. Canadian Biotech is a scam, and lenders are just there to take over the IP, not to see the company succeed.

consultant99 wrote: Bankrupcy?

Perhaps but ultimately if the loan is not repaid the leader converts to shares and there is massive dilution.

Ultimately shareholders get the same treatment - pennies on the dollar.

This is a sizable bet - great if it works and disaster if it doesn't. 
It looks like the value is there BUT no guarantee that the company can capture enough of it to pay off the loan in a timely fashion. So this is a very risky proposition; great reward but the potential to lose most or all of your investment. Not what shareholders were necessarily thinking when the company pushed through the spin-off.

All I did was point out what management has accomplished in the past.

Want more?

In 2009 the intraday high ($0.54) when FDA approval for Pennsaid was announced was worth more than $34/share post reverse split (i.e. after the company consolidated their share float). In less than 10 years more than 95% of market value has been destroyed. 

Anyways I still have a few shares left to remind me what happens when you think the company can turn it around. Maybe this time they will ...
 


 




<< Previous
Bullboard Posts
Next >>